BOONE, N.C., July 18, 2018 /PRNewswire/ -- Pneuma Respiratory, Inc., which has developed PNEUMAHALER™,,the first breath-activated digital inhaler (BDI), has raised $8.3 million in a Series A financing round.
Pneuma Respiratory, Inc. ("Pneuma") has developed the PNEUMAHALER™ Breath Activated Digital Inhaler
Eric Hunter, CEO and Founder of Pneuma Respiratory stated, " We are extremely gratified by the response to our Series A capital raise and look forward to continuing Pneuma's mission of developing greatly improved therapeutic treatments for patients who suffer from asthma and COPD."
About Pneuma Respiratory
Launched in 2015, Pneuma Respiratory is a pharmaceutical company based in Boone, North Carolina. With a global team of researchers, physicians, designers and engineers, Pneuma has created PNEUMAHALER™, the first fully integrated digital breath activated inhaler. The inhaled delivery system has integrated Bluetooth technology to provide feedback on drug delivery to patients, family members and health care providers. Using Pneuma's [proprietary/patented] digital droplet ejector technology, Pneuma's device, although currently available for investigational purposes only, has the potential to ultimately deliver a spectrum of novel therapies, including biologics, through the lungs. For more information visit www.pneumarespiratory.com
View original content:http://www.prnewswire.com/news-releases/pharmaceutical-company-pneuma-respiratory-raises-8-3-million-series-a-300683275.html
SOURCE Pneuma Respiratory
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All